Bionano Genomics, Inc. is a genomics company. The Company offers optical genome mapping (OGM) solutions for applications across basic, translational and clinical research. Through Lineagen, Inc., the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. It also offers a platform-agnostic software solution, which integrates sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants, and absence of heterozygosity across the genome in one consolidated view. The Company additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. The Company markets and sells OGM systems, including the Saphyr system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation (SV).
BörsenkürzelBNGO
Name des UnternehmensBionano Genomics Inc
IPO-datumAug 01, 2018
CEODr. R. Erik Holmlin, Ph.D.
Anzahl der mitarbeiter98
WertpapierartOrdinary Share
GeschäftsjahresendeAug 01
Addresse9540 Towne Centre Drive
StadtSAN DIEGO
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl92121
Telefon18588887600
Websitehttps://bionano.com/
BörsenkürzelBNGO
IPO-datumAug 01, 2018
CEODr. R. Erik Holmlin, Ph.D.
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten